TG Therapeutics

TGTX

Market cap $4.85B

The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.

TG Therapeutics (TGTX) is upgraded from Hold to Strong Buy as BRIUMVI demonstrates accelerating revenue growth and market share gains in the MS market. TGTX guides for 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% YoY growth and continued base expansion beyond Q4 2025 run rate. Strategic low pricing, administrative simplification, and subcutaneous formulation development underpin TGTX's competitive positioning and future margin expansion.

TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here's a look at the details.

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th Annual J.P.

TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.

Investors need to pay close attention to TGTX stock based on the movements in the options market lately.

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.

TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.